Navigation Links
Aida Files 10Q
Date:11/15/2007

SANTA MONICA, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that it has filed its form 10Q for the period ended September 30, 2007. Net revenues totaled $7,373,770 for the quarter ended 9/20/07, an increase of 5% over the same period in 2006. Gross profit decreased by 2.66% due to an increase in Costs of Goods Sold. Most notably, sales from Aida's transfusion and injection forms of etimicin sulfate increased markedly. Gross profit margins for Aida remained very strong, decreasing slightly from 55.81% to 51.75%.

Aida management expects the decrease in profits to be temporary. The Chinese pharmaceutical industry is in a state of transition due to policy changes by China's State Food and Drug Administration (SFDA). The new medicine tender system for hospitals in some areas in 2007 requires hospitals to purchase medicines and drugs directly from pharmaceutical manufacturers rather than distributors, which resulted in sales returns from some distributors. Aida has proactively and rapidly revised its distribution channels and is ready to compensate for the national policy changes. Aida also expects a strong showing from the new drugs in its pipeline that are coming to market in the coming quarters. Aida expects that these drugs will ease Aida's reliance on etimicin sulfate as a revenue generator and lessen the fluctuation in the Company's performance.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP c
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. Arrow International Files and Mails Definitive Proxy Materials
5. VaxGen Files 2006 Financial Statements and Provides Cash Update
6. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
7. Anacor Files Registration Statement for Initial Public Offering
8. IsoTis Files Definitive Proxy Statement
9. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
11. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier ... Dr. James L. Sherley, director of the Adult Stem ... on an often overlooked and under appreciated unique property ... Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, ... message to congress participants. He gave the address ...
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... FL (May 4, 2009): Uveitis, or inflammation within ... for years of visual loss roughly comparable to ... pioneering international Phase 3 program in uveitis, the ... ability of LX211 (LUVENIQ, voclosporin oral capsule) to ...
... Changes Will Result in a 35% Sales Force Reduction ... DIEGO, May 4 Amylin Pharmaceuticals, Inc. (Nasdaq: ... sales within the diabetes market. Amylin,s existing primary care ... organization that brings a specialty approach to endocrinologists and ...
... Diagnostics, LLC. (MSD) confirmed today that its investigational influenza ... of infection with the 2009 A(H1N1) swine flu. ... being developed under a contract with the Centers for ... referred to in the CDC,s Morbidity and Mortality Weekly ...
Cached Biology Technology:First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 2First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 3First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 4Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 2Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 3Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 4Meso Scale Diagnostics' Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Texas AgriLife Research program at Vernon could become a ... Malinowski, Texas AgriLife Research plant physiologist and forage agronomist ... early start about six years ago as a hobby ... Pinchak, AgriLife Research animal nutritionist, and Steve Brown, Texas ...
... "Paper of the Week" by Wai Mun Huang and ... the University of Minnesota reveals new insights into the molecular ... the pathogen responsible for crown gall disease, a tumor-forming infection ... The bacterium is parasitic: It infects its plant ...
... at the Northeast Fisheries Science Center,s Narragansett Laboratory, ... primary productivity and dissolved oxygen would lead. Now ... heads a long-term Ship of Opportunity Program (SOOP) ... platforms during their routine operations. Using an instrument, ...
Cached Biology News:Researchers take hibiscus efforts to commercialization 2Researchers take hibiscus efforts to commercialization 3NOAA plankton surveys, second longest in the North Atlantic, add to new global effort 2NOAA plankton surveys, second longest in the North Atlantic, add to new global effort 3
... monoclonal antibody which can immunocapture up to ... mitochondria. Also included are 2 mg of ... Complex V immunocapture kit allows isolation of ... small amounts of tissue. This facilitates subsequent ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
... Rabbit polyclonal to MKK6 (phospho S207) ... applications). Antigen: ... around the phosphorylation site of Serine ... Entrez Gene ID: 5608 ...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: